News & Updates

Accelerated cognitive decline risk with diabetes higher in women than men
Accelerated cognitive decline risk with diabetes higher in women than men
01 Nov 2021

Among patients with type 2 diabetes (T2D), women appear to be at greater risk of accelerated cognitive decline than men, as reported in a study. This risk increase can be partly explained by depressive symptoms being greater among women.

Accelerated cognitive decline risk with diabetes higher in women than men
01 Nov 2021
Pembrolizumab extends RFS in stage II melanoma
Pembrolizumab extends RFS in stage II melanoma
01 Nov 2021
Cancer patients bear brunt of COVID-19 pandemic
Cancer patients bear brunt of COVID-19 pandemic
01 Nov 2021

The COVID-19 pandemic has evidently affected the care and well-being of cancer patients, particularly those with advanced stages, reveals a recent study.

Cancer patients bear brunt of COVID-19 pandemic
01 Nov 2021
Noninvasive tests predict liver-related events in early alcohol-related liver disease
Noninvasive tests predict liver-related events in early alcohol-related liver disease
01 Nov 2021

In patients with early-stage alcohol-related liver disease, transient elastography (TE), the enhanced liver fibrosis test (ELF), and 2-dimensional shear-wave elastography (2D-SWE) can reliably predict the risk of symptomatic liver events, a recent study has found.

Noninvasive tests predict liver-related events in early alcohol-related liver disease
01 Nov 2021
Sustained benefit with anti-TNFα less likely to lead to subsequent loss of response in IBD
Sustained benefit with anti-TNFα less likely to lead to subsequent loss of response in IBD
01 Nov 2021

Inflammatory bowel disease (IBD) patients receiving treatment with antitumour necrosis factor alpha (anti-TNFα) for more than 2 years represent a distinct group who obtain prolonged clinical benefit and tolerate maintenance treatment, according to a study.

Sustained benefit with anti-TNFα less likely to lead to subsequent loss of response in IBD
01 Nov 2021